Maravai LifeSciences Holdings, Inc.
Sembol: MRVI
NASDAQ
9.86
USDBugünkü piyasa fiyatı
-9.9573
F/K Oranı
-0.0063
PEG Oranı
2.48B
MRK Kapağı
- 0.00%
DIV Verimi
Maravai LifeSciences Holdings, Inc. (MRVI) Finansal Tablolar
Bilanço
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2296.43 | 575 | 632.1 | 551.3 | ||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.net-receivables | 200.74 | 55.7 | 146.8 | 117.5 | ||||||
balance-sheet.row.inventory | 197.79 | 51.4 | 43.2 | 51.6 | ||||||
balance-sheet.row.other-current-assets | 73.01 | 17.8 | 25.8 | 19.7 | ||||||
balance-sheet.row.total-current-assets | 2767.97 | 699.9 | 847.9 | 740 | ||||||
balance-sheet.row.property-plant-equipment-net | 807.33 | 222.6 | 116.6 | 46.3 | ||||||
balance-sheet.row.goodwill | 1304.55 | 326 | 283.7 | 152.8 | ||||||
balance-sheet.row.intangible-assets | 897.69 | 221 | 216.7 | 117.6 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 2202.23 | 547 | 500.3 | 270.3 | ||||||
balance-sheet.row.long-term-investments | 35.81 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.tax-assets | 1764.23 | 0 | 765.8 | 808.1 | ||||||
balance-sheet.row.other-non-current-assets | -113.5 | 9.3 | 40.3 | 52.9 | ||||||
balance-sheet.row.total-non-current-assets | 4696.11 | 787.5 | 1434.4 | 1178.2 | ||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-assets | 7464.08 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.account-payables | 35.04 | 10.7 | 6 | 8.2 | ||||||
balance-sheet.row.short-term-debt | 45.01 | 12.9 | 11.7 | 9.7 | ||||||
balance-sheet.row.tax-payables | 1 | 1 | 1 | 1.4 | ||||||
balance-sheet.row.long-term-debt-total | 2192.18 | 518.7 | 573.6 | 524.6 | ||||||
Deferred Revenue Non Current | 829.37 | 79.4 | 0 | 0 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 21.59 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 209.03 | 60.5 | 89.4 | 65.7 | ||||||
balance-sheet.row.total-non-current-liabilities | 3807.23 | 610.1 | 1266.9 | 1279.1 | ||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.capital-lease-obligations | 285.32 | 79.4 | 57.8 | 3.7 | ||||||
balance-sheet.row.total-liab | 4106.89 | 697.6 | 1377.1 | 1372.9 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.common-stock | 10.05 | 2.5 | 2.6 | 2.6 | ||||||
balance-sheet.row.retained-earnings | 1349.25 | 285.7 | 404.8 | 184.6 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.other-total-stockholders-equity | 507.98 | 128.5 | 137.9 | 128.4 | ||||||
balance-sheet.row.total-stockholders-equity | 1867.28 | 416.8 | 545.2 | 315.5 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 7464.08 | 1487.5 | 2282.3 | 1918.3 | ||||||
balance-sheet.row.minority-interest | 1489.91 | 373.1 | 360 | 229.9 | ||||||
balance-sheet.row.total-equity | 3357.19 | 789.9 | 905.2 | 545.4 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 7464.08 | - | - | - | ||||||
Total Investments | 35.81 | 8.6 | 11.4 | 0.5 | ||||||
balance-sheet.row.total-debt | 2398.63 | 611 | 585.3 | 534.3 | ||||||
balance-sheet.row.net-debt | 102.2 | 36 | -46.9 | -17 |
Nakit Akış Tablosu
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -147.04 | -119 | 490.7 | 469.3 | ||||||
cash-flows.row.depreciation-and-amortization | 49.53 | 48.8 | 38.1 | 24.8 | ||||||
cash-flows.row.deferred-income-tax | 756.46 | 754.9 | 42.3 | 46.9 | ||||||
cash-flows.row.stock-based-compensation | 40.66 | 34.6 | 18.7 | 10.5 | ||||||
cash-flows.row.change-in-working-capital | 29.5 | 97.8 | -45.1 | -176.6 | ||||||
cash-flows.row.account-receivables | 19.87 | 84.4 | -22.3 | -70.4 | ||||||
cash-flows.row.inventory | 4.85 | 0.6 | 9.5 | -21.6 | ||||||
cash-flows.row.account-payables | 1.84 | 5.3 | -1.6 | 0.7 | ||||||
cash-flows.row.other-working-capital | 17.96 | 7.5 | -30.7 | -85.3 | ||||||
cash-flows.row.other-non-cash-items | -686.93 | -690.9 | -8.7 | -6.2 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 32.68 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -63.35 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.acquisitions-net | 75.02 | -69.6 | -238.3 | 120 | ||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-investing-activites | 6.42 | 12.9 | -12.2 | 0.5 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -56.82 | -122.3 | -267.6 | 105.7 | ||||||
cash-flows.row.debt-repayment | -5.92 | -5.8 | -13.9 | -6 | ||||||
cash-flows.row.common-stock-issued | -1.45 | 0 | 2.4 | 1.7 | ||||||
cash-flows.row.common-stock-repurchased | -0.35 | 0 | 0 | 0 | ||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-financing-activites | -35.07 | -55.3 | -176 | -154.8 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -42.44 | -61.1 | -187.5 | -159 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 1.6 | 0 | -0.1 | ||||||
cash-flows.row.net-change-in-cash | -66.58 | -57.2 | 80.9 | 315.1 | ||||||
cash-flows.row.cash-at-end-of-period | 2296.43 | 575 | 632.1 | 551.3 | ||||||
cash-flows.row.cash-at-beginning-of-period | 2363.02 | 632.1 | 551.3 | 236.2 | ||||||
cash-flows.row.operating-cash-flow | 32.68 | 126.2 | 536 | 368.6 | ||||||
cash-flows.row.capital-expenditure | -63.35 | -65.6 | -17.1 | -14.8 | ||||||
cash-flows.row.free-cash-flow | -30.67 | 60.7 | 518.9 | 353.7 |
Gelir Tablosu Satırı
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 274.1 | 288.9 | 883 | 799.2 | ||||||
income-statement-row.row.cost-of-revenue | 154 | 151.3 | 169 | 140.6 | ||||||
income-statement-row.row.gross-profit | 120.1 | 137.6 | 714 | 658.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 18.17 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.other-expenses | -1.5 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.operating-expenses | 166.92 | 141.8 | 147.6 | 115.3 | ||||||
income-statement-row.row.cost-and-expenses | 320.92 | 293.1 | 316.6 | 255.8 | ||||||
income-statement-row.row.interest-income | 28.89 | 27.7 | 2.3 | 30.3 | ||||||
income-statement-row.row.interest-expense | 23.2 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | 649.9 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | -1.5 | -1.3 | -0.4 | 0.3 | ||||||
income-statement-row.row.total-operating-expenses | 649.9 | 621.9 | -22.7 | -23.9 | ||||||
income-statement-row.row.interest-expense | 23.2 | 45.9 | 20.4 | 30.3 | ||||||
income-statement-row.row.depreciation-and-amortization | 25.72 | 48.8 | -5.8 | -11 | ||||||
income-statement-row.row.ebitda-caps | -19.96 | - | - | - | ||||||
income-statement-row.row.operating-income | -45.68 | -4.2 | 574.2 | 554.6 | ||||||
income-statement-row.row.income-before-tax | 599.85 | 617.7 | 551.5 | 530.8 | ||||||
income-statement-row.row.income-tax-expense | 759.56 | 756.1 | 60.8 | 61.5 | ||||||
income-statement-row.row.net-income | -131.04 | -119 | 490.7 | 469.3 |
Sıkça Sorulan Sorular
Nedir Maravai LifeSciences Holdings, Inc. (MRVI) toplam varlıklar?
Maravai LifeSciences Holdings, Inc. (MRVI) toplam varlıklar 1487450000.000 şeklindedir.
İşletmenin yıllık geliri nedir?
Yıllık gelir 138320000.000'dur.
Firma kâr marjı nedir?
Firma kar marjı 0.438'dir.
Şirket serbest nakit akışı nedir?
Serbest nakit akışı -0.232'dur.
İşletme net kar marjı nedir?
Net kâr marjı -0.478'dir.
Firma toplam geliri nedir?
Toplam gelir -0.167'dur.
Nedir Maravai LifeSciences Holdings, Inc. (MRVI) net kar (net gelir)?
Net kar (net gelir) -119029000.000'dur.
Firmanın toplam borcu nedir?
Toplam borç 610967000.000'dir.
Faaliyet giderleri rakamı nedir?
İşletme giderleri 141799000.000'dır.
Şirket nakit rakamı nedir?
İşletme içi nakit 561691000.000'tir.